Browse by category

New research from Saint Louis University School of Medicine and SSM Health has revealed weight loss medications could help dialysis patients qualify for kidney transplants. The study is among the largest to examine semaglutide in dialysis patients. These individuals are often excluded from transplant waitlists because a high body mass index (BMI) increases surgical risks and impacts outcomes after transplantation. Key findings: Patients lost an average of 20.5 pounds after on

High cost or insurance-related issues are the most common reasons for treatment discontinuation with semaglutide or tirzepatide for...

Semaglutide or tirzepatide should be the first line treatment for people living with obesity and most of its complications, according to...

Individuals who are taking semaglutide for weight loss experience less food noise than before, according to research presented at the...

Outcomes form the STEER real-world study have revealed that semaglutide 2.4 mg had 57% greater risk reduction for heart attack, stroke...

Women and older adults taking the anti-obesity drug semaglutide may be at higher risk for muscle loss, but higher protein intake may help...

Diabetic weight-loss medications are effective for people with schizophrenia without affecting psychotic symptoms, according to...

Semaglutide is associated with more than double the risk of developing neovascular age-related macular degeneration (nAMD) in older...

Interim results from the ongoing Phase 2 COURAGE trial - investigating novel combinations of semaglutide (GLP-1 receptor agonist) and...

Researchers at the Sahlgrenska Academy at the University of Gothenburg have shown that it is possible to distinguish the nerve cells in...